Courier Capital LLC bought a new stake in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 15,000 shares of the company’s stock, valued at approximately $75,000.
Other institutional investors have also added to or reduced their stakes in the company. Aire Advisors LLC acquired a new position in shares of ImmunityBio during the third quarter valued at about $25,000. Traynor Capital Management Inc. acquired a new position in ImmunityBio during the 3rd quarter valued at about $25,000. FMR LLC boosted its stake in ImmunityBio by 190.0% during the 3rd quarter. FMR LLC now owns 14,881 shares of the company’s stock valued at $25,000 after purchasing an additional 9,749 shares during the last quarter. Apollon Wealth Management LLC bought a new position in shares of ImmunityBio in the first quarter valued at approximately $25,000. Finally, WINTON GROUP Ltd purchased a new position in shares of ImmunityBio during the third quarter valued at approximately $26,000. 8.58% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, Piper Sandler increased their target price on shares of ImmunityBio from $4.00 to $5.00 and gave the company a “neutral” rating in a report on Monday.
ImmunityBio Price Performance
Shares of IBRX opened at $5.46 on Thursday. ImmunityBio, Inc. has a fifty-two week low of $1.25 and a fifty-two week high of $6.93. The business has a 50-day moving average of $4.57 and a 200 day moving average of $3.61.
About ImmunityBio
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.
See Also
- Five stocks we like better than ImmunityBio
- What is the S&P/TSX Index?
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- Consumer Staples Stocks, Explained
- 7 Stocks That Will Drive the Weight Loss Drugs Market
- What is a Death Cross in Stocks?
- Cintas or UniFirst: Investors Win Either Way
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
